In the past week, CGEM stock has gone down by -0.43%, with a monthly decline of -23.48% and a quarterly surge of 1.85%. The volatility ratio for the week is 5.90%, and the volatility levels for the last 30 days are 7.71% for Cullinan Therapeutics Inc The simple moving average for the past 20 days is -14.46% for CGEM’s stock, with a 17.18% simple moving average for the past 200 days.
Is It Worth Investing in Cullinan Therapeutics Inc (NASDAQ: CGEM) Right Now?
The stock has a 36-month beta value of -0.14. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for CGEM is 43.95M, and at present, short sellers hold a 10.29% of that float. On June 28, 2024, the average trading volume of CGEM was 921.29K shares.
CGEM) stock’s latest price update
The stock price of Cullinan Therapeutics Inc (NASDAQ: CGEM) has jumped by 1.55 compared to previous close of 17.09. Despite this, the company has seen a fall of -0.43% in its stock price over the last five trading days. globenewswire.com reported 2024-06-01 that Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed after prior amivantamab treatment Objective response rate of 39% with manageable safety profile in patients with non-small cell lung cancer (NSCLC) harboring EGFR Exon 20 insertion mutations treated with zipalertinib who had progressed after prior amivantamab treatment
Analysts’ Opinion of CGEM
Many brokerage firms have already submitted their reports for CGEM stocks, with Stifel repeating the rating for CGEM by listing it as a “Buy.” The predicted price for CGEM in the upcoming period, according to Stifel is $40 based on the research report published on May 01, 2024 of the current year 2024.
Wedbush gave a rating of “Outperform” to CGEM, setting the target price at $30 in the report published on February 15th of the current year.
CGEM Trading at -22.48% from the 50-Day Moving Average
After a stumble in the market that brought CGEM to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -42.51% of loss for the given period.
Volatility was left at 7.71%, however, over the last 30 days, the volatility rate increased by 5.90%, as shares sank -23.56% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -2.57% lower at present.
During the last 5 trading sessions, CGEM fell by -0.06%, which changed the moving average for the period of 200-days by +65.43% in comparison to the 20-day moving average, which settled at $20.02. In addition, Cullinan Therapeutics Inc saw 70.32% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at CGEM starting from Michaelson Jennifer, who sale 5,606 shares at the price of $30.06 back on May 07 ’24. After this action, Michaelson Jennifer now owns 129,582 shares of Cullinan Therapeutics Inc, valued at $168,516 using the latest closing price.
Michaelson Jennifer, the Chief Scientific Officer of Cullinan Therapeutics Inc, sale 58,000 shares at $28.07 during a trade that took place back on May 06 ’24, which means that Michaelson Jennifer is holding 129,582 shares at $1,628,159 based on the most recent closing price.
Stock Fundamentals for CGEM
The total capital return value is set at -0.4. Equity return is now at value -29.05, with -27.45 for asset returns.
Based on Cullinan Therapeutics Inc (CGEM), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -38.35.
Currently, EBITDA for the company is -190.34 million with net debt to EBITDA at 0.42. The liquidity ratio also appears to be rather interesting for investors as it stands at 20.33.
Conclusion
To sum up, Cullinan Therapeutics Inc (CGEM) has seen a mixed performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
